Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis

Stopped Terminated early due to lack of expected efficacy. Three participants were enrolled but none completed the study.

Conditions

• Palmoplantar Pustulosis

Interventions

• DRUG: Deucravacitinib

Sponsor

Peking University First Hospital